Reference: CapLaw-2014-15

On 7 April 2014, SIX Swiss Exchange listed biopharmaceutical company Newron Pharmaceuticals S.p.A. headquartered in Bresso/Milan, Italy, announced that in connection with a private placement it has raised gross proceeds of CHF 18.6 million, following the subscription by current institutional shareholders and new institutional investors joining from Europe and the US. The private placement was conducted without preferential subscription rights to institutional investors. The subscription price was set at CHF 15.75 per share, marginally below the closing price of Newron’s shares on 3 April 2014 of CHF 15.80.